07667nas a2202113   4500000000100000008004100001260001600042653002100058100001300079700001700092700001400109700001400123700001400137700001600151700001400167700001300181700001900194700001300213700001500226700001200241700001500253700001600268700001400284700001400298700001400312700001500326700001400341700001300355700001200368700001200380700001200392700002100404700002300425700002000448700001500468700001500483700002000498700001300518700001300531700001400544700001800558700001200576700001200588700001200600700001000612700001700622700001400639700001300653700001000666700001100676700001400687700001400701700001700715700001200732700001100744700001700755700001300772700001500785700001500800700001500815700001700830700001400847700001600861700001500877700001600892700001500908700001400923700001900937700001300956700001700969700001500986700001301001700001501014700001701029700001501046700001101061700001401072700001001086700001301096700001301109700001501122700001201137700001201149700001401161700001501175700001001190700001401200700001301214700001201227700001401239700001501253700001701268700001201285700001401297700001401311700001101325700001101336700001101347700001101358700001501369700001301384700001601397700001501413700001501428700001401443700001301457700001301470700001501483700001601498700001701514700002901531700002401560700001401584700001401598700001301612700001301625700001401638700001301652700001401665700001501679700001501694700001601709700001501725700001801740700001501758700001101773700001701784700001501801700001401816700001201830700001301842700001301855700001301868700001501881700001101896700001501907700001201922700001301934700001301947700001401960700001201974700001401986700001202000700001302012700001602025700001302041700001402054700001502068700001702083700001502100700001402115700001502129700001602144700001702160700001502177700001502192700001302207700001502220700001502235700001202250700001802262700001902280700001202299700001402311700001202325700001102337700001202348700001202360700001202372700001402384700001302398700001002411245014402421856007502565300001402640490000602654520287902660022001405539       2021                            d  bElsevier BV10aGeneral Medicine1 aBourne R1 aSteinmetz JD1 aFlaxman S1 aBriant PS1 aTaylor HR1 aResnikoff S1 aCasson RJ1 aAbdoli A1 aAbu-Gharbieh E1 aAfshin A1 aAhmadieh H1 aAkalu Y1 aAlamneh AA1 aAlemayehu W1 aAlfaar AS1 aAlipour V1 aAnbesu EW1 aAndroudi S1 aArabloo J1 aArditi A1 aAsaad M1 aBagli E1 aBaig AA1 aBärnighausen TW1 aBattaglia Parodi M1 aBhagavathula AS1 aBhardwaj N1 aBhardwaj P1 aBhattacharyya K1 aBijani A1 aBikbov M1 aBottone M1 aBraithwaite T1 aBron AM1 aButt ZA1 aCheng C1 aChu D1 aCicinelli MV1 aCoelho JM1 aDagnew B1 aDai X1 aDana R1 aDandona L1 aDandona R1 aDel Monte MA1 aDeva JP1 aDiaz D1 aDjalalinia S1 aDreer LE1 aEhrlich JR1 aEllwein LB1 aEmamian MH1 aFernandes AG1 aFischer F1 aFriedman DS1 aFurtado JM1 aGaidhane AM1 aGaidhane S1 aGazzard G1 aGebremichael B1 aGeorge R1 aGhashghaee A1 aGolechha M1 aHamidi S1 aHammond BR1 aHartnett MER1 aHartono RK1 aHay SI1 aHeidari G1 aHo HC1 aHoang CL1 aHouseh M1 aIbitoye SE1 aIlic IM1 aIlic MD1 aIngram AD1 aIrvani SSN1 aJha R1 aKahloun R1 aKandel H1 aKasa AS1 aKempen JH1 aKeramati M1 aKhairallah M1 aKhan EA1 aKhanna RC1 aKhatib MN1 aKim JE1 aKim YJ1 aKisa S1 aKisa A1 aKoyanagi A1 aKurmi OP1 aLansingh VC1 aLeasher JL1 aLeveziel N1 aLimburg H1 aMajdan M1 aManafi N1 aMansouri K1 aMcAlinden C1 aMohammadi SF1 aMohammadian-Hafshejani A1 aMohammadpourhodki R1 aMokdad AH1 aMoosavi D1 aMorse AR1 aNaderi M1 aNaidoo KS1 aNangia V1 aNguyen CT1 aNguyen HLT1 aOgundimu K1 aOlagunju AT1 aOstroff SM1 aPanda-Jonas S1 aPesudovs K1 aPeto T1 aQuazi Syed Z1 aRahman MHU1 aRamulu PY1 aRawaf S1 aRawaf DL1 aReinig N1 aRobin AL1 aRossetti L1 aSafi S1 aSahebkar A1 aSamy AM1 aSaxena D1 aSerle JB1 aShaikh MA1 aShen TT1 aShibuya K1 aShin JI1 aSilva JC1 aSilvester A1 aSingh JA1 aSinghal D1 aSitorus RS1 aSkiadaresi E1 aSkirbekk V1 aSoheili A1 aSousa RARC1 aSpurlock EE1 aStambolian D1 aTaddele BW1 aTadesse EG1 aTahhan N1 aTareque MI1 aTopouzis F1 aTran BX1 aTravillian RS1 aTsilimbaris MK1 aVarma R1 aVirgili G1 aWang YX1 aWang N1 aWest SK1 aWong TY1 aZaidi Z1 aZewdie KA1 aJonas JB1 aVos T00aTrends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study  uhttps://www.thelancet.com/action/showPdf?pii=S2214-109X%2820%2930425-3  ae130-e1430 v93 aBackground<br>
To contribute to the WHO initiative, VISION 2020: The Right to Sight, an assessment of global vision impairment in 2020 and temporal change is needed. We aimed to extensively update estimates of global vision loss burden, presenting estimates for 2020, temporal change over three decades between 1990–2020, and forecasts for 2050.<br>
<br>Methods<br>
We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. Only studies with samples representative of the population and with clearly defined visual acuity testing protocols were included. We fitted hierarchical models to estimate 2020 prevalence (with 95% uncertainty intervals [UIs]) of mild vision impairment (presenting visual acuity ≥6/18 and <6/12), moderate and severe vision impairment (<6/18 to 3/60), and blindness (<3/60 or less than 10° visual field around central fixation); and vision impairment from uncorrected presbyopia (presenting near vision <N6 or <N8 at 40 cm where best-corrected distance visual acuity is ≥6/12). We forecast estimates of vision loss up to 2050.<br>
<br>Findings<br>
In 2020, an estimated 43·3 million (95% UI 37·6–48·4) people were blind, of whom 23·9 million (55%; 20·8–26·8) were estimated to be female. We estimated 295 million (267–325) people to have moderate and severe vision impairment, of whom 163 million (55%; 147–179) were female; 258 million (233–285) to have mild vision impairment, of whom 142 million (55%; 128–157) were female; and 510 million (371–667) to have visual impairment from uncorrected presbyopia, of whom 280 million (55%; 205–365) were female. Globally, between 1990 and 2020, among adults aged 50 years or older, age-standardised prevalence of blindness decreased by 28·5% (–29·4 to −27·7) and prevalence of mild vision impairment decreased slightly (–0·3%, −0·8 to −0·2), whereas prevalence of moderate and severe vision impairment increased slightly (2·5%, 1·9 to 3·2; insufficient data were available to calculate this statistic for vision impairment from uncorrected presbyopia). In this period, the number of people who were blind increased by 50·6% (47·8 to 53·4) and the number with moderate and severe vision impairment increased by 91·7% (87·6 to 95·8). By 2050, we predict 61·0 million (52·9 to 69·3) people will be blind, 474 million (428 to 518) will have moderate and severe vision impairment, 360 million (322 to 400) will have mild vision impairment, and 866 million (629 to 1150) will have uncorrected presbyopia.<br>
<br>Interpretation<br>
Age-adjusted prevalence of blindness has reduced over the past three decades, yet due to population growth, progress is not keeping pace with needs. We face enormous challenges in avoiding vision impairment as the global population grows and ages.  a2214-109X